155 related articles for article (PubMed ID: 26408685)
61. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
62. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
63. Urokinase receptor expression involves tyrosine phosphorylation of phosphoglycerate kinase.
Shetty P; Velusamy T; Bhandary YP; Liu MC; Shetty S
Mol Cell Biochem; 2010 Feb; 335(1-2):235-47. PubMed ID: 19784757
[TBL] [Abstract][Full Text] [Related]
64. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells.
Henic E; Noskova V; Høyer-Hansen G; Hansson S; Casslén B
Int J Gynecol Cancer; 2009 Feb; 19(2):214-22. PubMed ID: 19395996
[TBL] [Abstract][Full Text] [Related]
65. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.
Zhang Y; Kenny HA; Swindell EP; Mitra AK; Hankins PL; Ahn RW; Gwin K; Mazar AP; O'Halloran TV; Lengyel E
Mol Cancer Ther; 2013 Dec; 12(12):2628-39. PubMed ID: 24061648
[TBL] [Abstract][Full Text] [Related]
66. Lysophosphatidic acid-induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer.
Choi KU; Yun JS; Lee IH; Heo SC; Shin SH; Jeon ES; Choi YJ; Suh DS; Yoon MS; Kim JH
Int J Cancer; 2011 Jan; 128(2):332-42. PubMed ID: 20309942
[TBL] [Abstract][Full Text] [Related]
67. ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.
Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
[TBL] [Abstract][Full Text] [Related]
68. Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Rysenkova KD; Klimovich PS; Shmakova AA; Karagyaur MN; Ivanova KA; Aleksandrushkina NA; Tkachuk VA; Rubina KA; Semina EV
Cell Signal; 2020 Nov; 75():109741. PubMed ID: 32822758
[TBL] [Abstract][Full Text] [Related]
69. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.
Devine KM; Smicun Y; Hope JM; Fishman DA
Gynecol Oncol; 2008 Aug; 110(2):237-45. PubMed ID: 18513786
[TBL] [Abstract][Full Text] [Related]
70. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Young TN; Rodriguez GC; Moser TL; Bast RC; Pizzo SV; Stack MS
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1285-96. PubMed ID: 8178854
[TBL] [Abstract][Full Text] [Related]
71. Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.
Jeong BY; Cho KH; Yoon SH; Park CG; Park HW; Lee HY
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065317
[TBL] [Abstract][Full Text] [Related]
72. Chemical Analysis of Morphological Changes in Lysophosphatidic Acid-Treated Ovarian Cancer Cells.
Bailey KA; Klymenko Y; Feist PE; Hummon AB; Stack MS; Schultz ZD
Sci Rep; 2017 Nov; 7(1):15295. PubMed ID: 29127342
[TBL] [Abstract][Full Text] [Related]
73. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Gonias SL; Hembrough TA; Sankovic M
Front Biosci; 2001 Nov; 6():D1403-11. PubMed ID: 11689350
[TBL] [Abstract][Full Text] [Related]
74. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.
Mukherjee A; Wu J; Barbour S; Fang X
J Biol Chem; 2012 Jul; 287(30):24990-5000. PubMed ID: 22665482
[TBL] [Abstract][Full Text] [Related]
75. Differential roles of uPAR in peritoneal ovarian carcinomatosis.
Al-Hassan NN; Behzadian A; Caldwell R; Ivanova VS; Syed V; Motamed K; Said NA
Neoplasia; 2012 Apr; 14(4):259-70. PubMed ID: 22577342
[TBL] [Abstract][Full Text] [Related]
76. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Fang X; Gaudette D; Furui T; Mao M; Estrella V; Eder A; Pustilnik T; Sasagawa T; Lapushin R; Yu S; Jaffe RB; Wiener JR; Erickson JR; Mills GB
Ann N Y Acad Sci; 2000 Apr; 905():188-208. PubMed ID: 10818454
[TBL] [Abstract][Full Text] [Related]
77. uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium.
Stewart CE; Nijmeh HS; Brightling CE; Sayers I
Thorax; 2012 Jun; 67(6):477-87. PubMed ID: 22139533
[TBL] [Abstract][Full Text] [Related]
78. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.
Fang X; Yu S; Bast RC; Liu S; Xu HJ; Hu SX; LaPushin R; Claret FX; Aggarwal BB; Lu Y; Mills GB
J Biol Chem; 2004 Mar; 279(10):9653-61. PubMed ID: 14670967
[TBL] [Abstract][Full Text] [Related]
79. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
Li Santi A; Napolitano F; Montuori N; Ragno P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923400
[TBL] [Abstract][Full Text] [Related]
80. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
Chen H; Hao J; Wang L; Li Y
Br J Cancer; 2009 Aug; 101(3):432-40. PubMed ID: 19603017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
